Gamida Cell - Cord Blood Transplant

Scientific Publications

Successful Engraftment and Cure of Sickle Cell Disease after Co-transplantation of NiCord® (Ex Vivo Expanded UCB Progenitor Cells with Nicotinamide) and a Second Unmanipulated Cord Blood Unit after Myeloablative Chemotherapy in Children with Severe Sickle Cell Disease
Dec. 29, 2016

NiCord Single Unit Expanded Umbilical Cord Blood Transplantation: Results of Phase I/II Trials
Dec. 29, 2016

Results of Nicord Phase I–II Trials and Plans for Phase III Trial
Jun. 10, 2016

Transplantation of Ex vivo Expanded Umbilical Cord Blood (NiCord®) Results in Decreased Infection Burden and Hospital Length of Stay in the First 100 Days
Apr. 5, 2016

Nicord Expands Haematopoietic Stem Cells and Provides Prompt and Durable Engraftment in Patients Undergoing Cord Blood Transplantation for Haematological Malignancies and Sickle Cell Disease: Results of Early Phase Clinical Trials using Fresh and Crypreserved Product
Mar. 5, 2015

Umbilical Cord Blood Expansion with Nicotinamide Provides Long-term Multilineage Engraftment
Jul. 1, 2014

Improved Homing To Bone Marrow, Spleen and Lung Of Adoptively Infused NK Cells Expanded Ex Vivo With The Small Molecule Nicotinamide Using Feeder-Free Conditions
Dec. 10, 2013

StemEx® (Copper Chelation Based) Ex Vivo Expanded Umbilical Cord Blood Stem Cell Transplantation (UCBT) Accelerates Engraftment and Improves 100 Day Survival In Myeloablated Patients Compared To a Registry Cohort Undergoing Double Unit UCBT: Results Of a Multicenter Study Of 101 Patients With Hematologic Malignancies
Dec. 7, 2013

Nicotinamide, a SIRT1 Inhibitor, Inhibits Differentiation and Facilitates Expansion of Hematopoietic Progenitor Cells with Enhanced Bone Marrow Homing and Engraftment
Jan. 18, 2012

Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine- a phase I-II clinical trial
Jan. 21, 2008

Nicotinamide Modulates Ex-Vivo Expansion of Cord Blood Derived CD34+ Cells Cultured with Cytokines and Promotes Their Homing and Engraftment in SCID Mice
Dec. 12, 2006

Nicotinamide, a Specific Inhibitor of NAD(+)-Dependent ADP-ribosyl Transferases Promotes Ex-Vivo Expansion of Early Subsets of Hemopoietic CD34+ Cells
Dec. 12, 2006

Nicotinamide Modulates Ex-Vivo Expansion of Cord Blood Derived CD34+ Cells Cultured with Cytokines and Promotes Their Homing and Engraftment in SCID Mice
Dec. 12, 2006

Antagonists to Retinoid Receptors Down-Regulate CD38 Expression and Inhibit In Vitro Differentiation of Cord Blood Derived CD34+ Cells
Dec. 11, 2006

Nicotinamide Attenuates In Vitro Differentiation and Elevates Bone Marrow Homing Potential of Cultured CD34+ Cells
Jan. 1, 2006

Chelatable cellular copper modulates differentiation and self-renewal of cord blood-derived hematopoietic progenitor cells
Jun. 2, 2005

Linear polyamine copper chelator tetraethylenepentamine augments long-term ex vivo expansion of cord blood-derived CD34(+) cells and increases their engraftment potential in NOD/SCID mice. Exp Hematol. 2004;32:547-55
Mar. 9, 2004

Pre-clinical development of cord blood-derived progenitor cell graft expanded ex vivo with cytokines and the polyamine copper chelator tetraethylenepentamine. Cytotherapy 2004;6:344-55
Jan. 1, 2004

The Effect of Tetraethylenepentamine, a Synthetic Copper Chelating Polyamine, on Expression of CD34 and CD38 Antigens on Normal and Leukemic Hematopoietic Cells Leukemia & Lymphoma, March 2004 Vol. 45 (3), pp. 583ן¿½589
Jun. 15, 2003

Cellular copper content modulates differentiation and self-renewal in cultures of cord blood-derived CD34+ cells. Br J Haematol. 2002;116:655-661
Oct. 2, 2001

Ex-vivo Expanded Human Bone Marrow-Derived CD133+ Cells Improve Cardiac Function in Rats With Acute Myocardial Infarction
Jan. 1, 2001

To learn more about our products and clinical trials, please fill in:
* Message: